Abstract: In one aspect, the present disclosure relates to compounds which inhibit one or more ?-lactamases and/or penicillin binding proteins (PBPs), and pharmaceutical compositions thereof. In another aspect, the present disclosure provides a method of treating, preventing, and/or ameliorating a bacterial infection in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one compound of the present disclosure and/or at least one pharmaceutical composition of the present disclosure. In certain embodiments, the ?-lactamase is selected from the group consisting of NDM-1, KPC-2, and OXA-48. In certain embodiments, the PBP is PBP-3.

Abstract: In one aspect, the present disclosure provides compounds which inhibit a coronavirus main protease. In another aspect, the present disclosure provides a method of treating, ameliorating and/or preventing a coronavirus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of the disclosure. In some embodiments, the method prevents or treats COVID-19 in the subject.

Abstract: The disclosure relates, in certain aspects, to compounds that can be used to inhibit ?-lactamases, such as but not limited to OXA enzymes, such as but not limited to OXA-24, OXA-48, and/or OXA-58. In certain embodiments, these compounds can be used to inhibit activity of ?-lactamases in vitro and in vivo.

Abstract: The disclosure relates, in certain aspects, to compounds that can be used to inhibit ?-lactamases, such as but not limited to OXA enzymes, such as but not limited to OXA-24, OXA-48, and/or OXA-58. In certain embodiments, these compounds can be used to inhibit activity of ?-lactamases in vitro and in vivo.

Abstract: The present invention concerns methods and/or compositions for treatment and/or prevention of bacterial infection wherein the bacteria has at least one metallo-?-lactamase. The bacteria are provided with an inhibitor of the metallo-?-lactamase, for example in conjunction with an antibiotic that targets the bacteria. The bacteria may be a drug-resistant strain or susceptible to becoming a drug-resistant strain. In specific embodiments, the bacteria is Pseudomonas or Acinetobacter spp.

Abstract: The present invention concerns compositions and methods for detecting Norovirus or Norovirus particles. In particular, the present invention encompasses antibodies for detecting Norovirus or Norovirus particles, including, for example, monoclonal antibodies that have broad specificity of binding to various genogroups of norovirus.

Abstract: Noroviruses are recognized as the most common cause of outbreaks of acute gastroenteritis in humans. Therefore, the present invention relates to peptides or dendrimers that bind Noroviruses and the methods for identifying and synthesizing these peptides. It also relates to the detection of Noroviruses using said peptides or dendrimers formed by them.

Abstract: Peptide inhibitors of ?-lactamases have been identified by the synthesis of peptide arrays using synthesis SPOT technology. These peptide inhibitors of ?-lactamase have activity against a broad spectrum of ?-lactamases and are useful in a variety of applications.

Abstract: The invention relates to methods and mutation linkers to modify DNA, to methods for producing libraries containing a multiplicity of modified DNA, and to methods for using such libraries for screening modified proteins encoded by such DNA. The DNA targeted for modification typically encodes a polypeptide such as an enzyme. The libraries are used to determine the effect of such modification or the interaction of the modified polypeptides with a target. In preferred embodiments, the invention relates to methods for making and using libraries containing DNA encoding modified antibiotic hydrolases to screen antibiotics against one or more of the modified antibiotic hydrolases produced by such libraries. Susceptibility or lack of susceptibility of an antibiotic to neutralization provides an indication of whether wild-type antibiotic hydrolases are likely to mutate to confer resistance to the antibiotic.